Personally I've become more bullish on 701 in part based on anectdotal reports of some patients (who still haven't been put on the 20mg/kg dose) and Genzyme/SNY's continued ERT manufacturing woe's.
On PEG-PAL I think we still need to see the data. The program has some questions in my mind and I don't see it as having the big potential I once thought.
GALNS is still the key...of course Zacks likes to talk about Firdapse (disappointing) :-)